11/23/2020 1:05:48 AM
Argenx Agrees To Buy FDA Priority Review Voucher From Bayer Healthcare Pharmaceuticals For $98 Mln
10/5/2020 1:14:09 AM
Argenx Presents New Data From Pivotal Phase 3 ADAPT Trial Evaluating Efgartigimod
5/29/2020 1:08:44 AM
Argenx Reports Full Exercise Of Underwriters' Option To Purchase Addl ADSs
5/28/2020 12:25:42 AM
Argenx Announces Pricing Of $750 Mln Of Global Offering Of Ordinary Shares
5/26/2020 1:09:50 AM
Argenx Reports Positive Topline Data From Pivotal ADAPT Trial Of Efgartigimod
2/4/2019 1:02:11 AM
Argenx, Halozyme Therapeutics Enter Global Collaboration And License Agreement For ENHANZE Technology
12/17/2018 2:31:47 AM
Forbion Portfolio Company Staten Biotechnology Enters Into Collaboration With Novo Nordisk
12/3/2018 1:02:31 AM
Argenx Enters Global Collaboration And License Agreement With Cilag GmbH International For Cusatuzumab (ARGX-110)
12/3/2018 1:01:46 AM
Argenx Provides Detailed Data From Phase 2 Clinical Trial Of Efgartigimod In Immune Thrombocytopenia
8/22/2018 2:04:24 AM
Argenx Announces Exercise Of Its Exclusive License Option To Develop And Commercialize ARGX-115
6/28/2018 1:03:07 AM
Argenx Announces Achievement Of Second Of Two Preclinical Milestones Towards IND Filing For ARGX-115